Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q1 FY20 results · Apr–Jun 2019
Jubilant Pharmova reported revenue from operations of ₹2,181.86 crore (up 5.0% from Q1 FY19) and net profit of ₹184.98 crore (down 7.7% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,181.86 | 2,078.65 | +5.0% | 2,385.58 | −8.5% |
| Other income | 9.70 | 9.47 | +2.4% | (6.58) | Turned profit |
| Total income | 2,191.56 | 2,088.12 | +5.0% | 2,379.00 | −7.9% |
| Profit before tax | 269.03 | 286.37 | −6.1% | (39.98) | Turned profit |
| Net profit for the period | 184.98 | 200.37 | −7.7% | (100.65) | Turned profit |
| EPS, basic (₹) | 11.61 | 13.00 | −10.7% | (6.38) | Turned profit |
| Net margin (%) | 8.5 | 9.6 | -4.2 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 789.82 | 826.64 | −4.5% | 865.12 | −8.7% |
| Other income | 5.94 | 4.41 | +34.7% | 4.83 | +23.0% |
| Total income | 795.76 | 831.05 | −4.2% | 869.95 | −8.5% |
| Profit before tax | 47.32 | 33.45 | +41.5% | 6.39 | +640.5% |
| Net profit for the period | 32.26 | 23.88 | +35.1% | 7.44 | +333.6% |
| EPS, basic (₹) | 2.03 | 1.50 | +35.3% | 0.47 | +331.9% |
| Net margin (%) | 4.1 | 2.9 | 0.9 |
Consolidated
- Filed with BSE
- 26 Jul 2019, 17:43 IST
- Board meeting
- 26 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Jul 2019, 17:43 IST
- Board meeting
- 26 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE